SCHEMBL4583967

SCHEMBL4583967

CC(C)C=CC(F)(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11890395 1.00
SCHEMBL12736716 1.00
SCHEMBL24375382 0.78
SCHEMBL5157165 0.75
SCHEMBL809056 0.75
SCHEMBL16786164 0.75
SCHEMBL10931279 0.75
SCHEMBL809057 0.75
SCHEMBL7970728 0.75
SCHEMBL15147670 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951838-A2 COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF E.I. DU PONT DE NEMOURS AND COMPANY (US) 2008-08-06 EP disclosed
WO-2007053697-A2 COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-05-10 WO disclosed
US-6506775-B1 Treatment of a gastrointestinal disorder; a central nervous system (CNS) adverse conditions caused by Heliobacter pylori; or angiogenesis especially CNS disorders in a mammalian subject, especially humans. PFIZER INC 2003-01-14 US disclosed
US-6329396-B1 TREATMENT OF GASTROINTESTINAL DISORDERS CENTRAL NERVOUS SYSTEM (CNS) DISORDERS; INFLAMMATORY DISEASE; EMESIS; URINARY INCONTINENCE; PAIN; MIGRAINE; SUNBURN; DISEASES, DISORDERS AND ADVERSE CONDITIONS CAUSED BY HELIOBACTER PYLORI; OR PFIZER INC. 2001-12-11 US disclosed
EP-0861235-B1 SUBSTITUTED BENZYLAMINOPIPERIDINE COMPOUNDS PFIZER (US) 2001-11-07 EP disclosed
EP-1114817-A1 Substituted benzylamino piperidine compounds PFIZER INC. (US) 2001-07-11 EP disclosed